Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneys
Public ClinicalTrials.gov record NCT05714514. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Long-term Confirmatory Follow up Trial in Highly Sensitized Patients Treated With Imlifidase or Standard of Care in the ConfIdeS (20-HMedIdeS-17) Trial
Study identification
- NCT ID
- NCT05714514
- Recruitment status
- Active, not recruiting
- Study type
- Observational
- Phase
- Not listed
- Lead sponsor
- Hansa Biopharma AB
- Industry
- Enrollment
- 64 participants
Conditions and interventions
Interventions
- Imlifidase administered in the ConfIdeS study Drug
- Best available treatment administered in the ConfIdeS study Other
Drug · Other
Eligibility (public fields only)
- Age range
- Not listed
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Apr 20, 2023
- Primary completion
- Dec 30, 2027
- Completion
- Dec 30, 2029
- Last update posted
- Nov 17, 2025
2023 – 2029
United States locations
- U.S. sites
- 14
- U.S. states
- 11
- U.S. cities
- 12
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| University of Alabama at Birmingham (UAB) Hospital | Birmingham | Alabama | 35249 | — |
| Cedars-Sinai Medical Center | Los Angeles | California | 90048 | — |
| Northwestern University, Dept. General Surgery, Div. Transplantation | Chicago | Illinois | 60611 | — |
| University of Chicago, Department of Surgery, Clinical Research Center | Chicago | Illinois | 60637 | — |
| John Hopkins Hospital | Baltimore | Maryland | 21287 | — |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | — |
| Washington University School of Medicine | St Louis | Missouri | 63110 | — |
| Cooperman Barnabas Medical Center | Livingston | New Jersey | 07039 | — |
| New York University (NYU) Langone Transplant Institute, NYU Langone Health | New York | New York | 10016 | — |
| Columbia University | New York | New York | 10032 | — |
| Houston Methodist Hospital | Houston | Texas | 77030 | — |
| Methodist Hospital Specialty and Transplant | San Antonio | Texas | 78229 | — |
| University of Washington Medical Center | Seattle | Washington | 98195 | — |
| Medical College of Wisconsin | Milwaukee | Wisconsin | 53226 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT05714514, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Nov 17, 2025 · Synced Jul 23, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT05714514 live on ClinicalTrials.gov.